X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
Tags:
Thumbnail
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study. [Read More]
Sarepta Therapeutics Inc. undefined shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on... [Read More]
Sarepta Therapeutics Inc. SRPT, +5.14% ... [Read More]
Sarepta Therapeutics, Inc. SRPT, the leader... [Read More]
Thumbnail
Check out the stocks making notable moves after the bell on Thursday, June 23. [Read More]
Save As
Preview
Preview